LIFT Chicago

LIFT BioSciences is a clinical-stage biotechnology company pioneering a new class of allogeneic innate cell therapies called Immuno-Modulatory Alpha Neutrophils (IMANs). The company's proprietary N-LIFT platform produces high-potency, cancer-killing neutrophils derived from exceptional donors, designed to overcome the limitations of current immunotherapies in treating solid tumors. These IMANs work through a multimodal mechanism of action, directly killing cancer cells while simultaneously immunomodulating the tumor microenvironment to orchestrate a broader immune response. LIFT is currently advancing its lead program toward first-in-human clinical trials, with a primary focus on hard-to-treat indications such as pancreatic and lung cancers.